Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator

摘要

The use of (i) a substance capable of: activating at least one PKC isoform selected from PKC-gamma, PKC-eta, PKC-epsilon, PKC-zeta; or inhibiting at least one PKC isoform selected from PKC-alpha, PKC-eta, PKC-beta, PKC-zeta and PKC-epsilon; and (ii) at least one additional agent selected from the group consisting of an adipokine, PKC-delta RACK and GW9662 adopted for topical administration for inducing or accelerating a healing process of a damaged skin or skin wound. With the proviso that the combinations of: PCK-alpha and adiponectin; and PKC-alpha and GW9662; and PKC-zeta and PKC-delta RACK; and PKC-zeta and GW9662 are excluded. In particular the inhibitor can be an N-myristoylated PKC isoform pseudosubstrate peptide.